Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.

Read More